Market Overview

Novocure and US Oncology Research Announce Collaboration on PANOVA-3 Trial for Patients with Advanced Pancreatic Cancer


US Oncology Research will open 10 clinical trial sites, enrolling
patients in Novocure's PANOVA-3 trial to test the efficacy of Tumor
Treating Fields combined with nab-paclitaxel and gemcitabine in patients
with unresectable locally advanced pancreatic cancer

Novocure (NASDAQ:NVCR) and US
Oncology Research
are collaborating on PANOVA-3, a phase 3 pivotal
trial testing the efficacy of Tumor Treating Fields combined with
nab-paclitaxel and gemcitabine in patients with unresectable locally
advanced pancreatic cancer. Tumor Treating Fields is a cancer therapy
that uses electric fields tuned to specific frequencies to disrupt cell
division, inhibiting tumor growth and causing affected cancer cells to
die. US Oncology Research, supported by The
US Oncology Network
– one of the largest networks of integrated,
community-based oncology practices – will open 10 clinical trial sites
enrolling patients in Novocure's PANOVA-3 trial.

"Pancreatic cancer is one of the most aggressive forms of cancer and was
the third leading cause of cancer death in the U.S. last year," said
Daniel D. Von Hoff, M.D., F.A.C.P., Principal Investigator for PANOVA-3,
Physician in Chief, Distinguished Professor at the Translational
Genomics Research Institute in Phoenix and the Chief Scientific Officer
for US Oncology Research. "I believe Tumor Treating Fields has the
potential to improve survival in this disease. I am pleased to have US
Oncology Research's support."

PANOVA-3 is a randomized, open-label trial that will include 556
patients with unresectable locally advanced pancreatic cancer. Patients
should have an Eastern Cooperative Oncology Group (ECOG) score of 0-2
and no prior progression or treatment. Patients in the experimental arm
will use a Tumor Treating Fields delivery system tuned to 150 kHz for at
least 18 hours a day until the disease progresses. The primary trial
endpoint is overall survival. The secondary endpoints include
progression free survival, local progression free survival, objective
response rate, one-year survival rate, quality of life, pain-free
survival, resectability rate and toxicity.1

"Our strategic collaboration with US Oncology Research is an important
milestone as we aim to bring better treatment options to patients with
pancreatic cancer," said Dr. Eilon Kirson, Novocure's Chief Science
Officer and Head of Research and Development. "We believe this
relationship will accelerate enrollment of patients in our PANOVA-3
trial. We look forward to working with US Oncology Research and The US
Oncology Network to advance cancer care."

About Pancreatic Cancer

Pancreatic cancer was the third leading cause of cancer death in the
U.S. in 2017. Five-year survival among patients with pancreatic cancer
is about 8 percent. The American Cancer Society estimated that about
53,000 people would be diagnosed with pancreatic cancer and about 43,000
people would die from the disease in 2017. Worldwide, more than 330,000
people die from the disease every year.

About US Oncology Research

Supported by McKesson
Specialty Health
 and The
US Oncology Network
, US Oncology Research draws from a network of
experienced investigators and dedicated clinical staff who specialize in
oncology clinical trials. US Oncology Research serves approximately 60
research sites and more than 150 locations managing about 300 active
trials at any given time. Physicians in the research network have
enrolled more than 75,000 patients in over 1,600 trials since inception
about two decades ago and have played a role in more than 75
FDA-approved cancer therapies, approximately one-third of all cancer
therapies approved by the FDA to date. For more information, visit

About The US Oncology Network

Every day, The US Oncology Network (The Network) helps more than 1,400
independent physicians deliver value-based, integrated care for patients
–close to home. Through The Network, these independent doctors come
together to form a community of shared expertise and resources dedicated
to advancing local cancer care and to delivering better patient
outcomes. The Network provides doctors with access to coordinated
resources, best business practices, and the experience, infrastructure
and support of McKesson Specialty Health. This collaboration allows the
doctors in The Network to focus on the health of their patients, while McKesson
focuses on the health of their practices. Together, The Network and its
affiliated physicians are committed to the success of independent
practices, everywhere. For more information, visit

About Novocure

Novocure is an oncology company developing a profoundly different cancer
treatment utilizing a proprietary therapy called Tumor Treating Fields,
the use of electric fields tuned to specific frequencies to disrupt
solid tumor cancer cell division. Novocure's commercialized product is
approved for the treatment of adult patients with glioblastoma. Novocure
has ongoing or completed clinical trials investigating Tumor Treating
Fields in brain metastases, non-small cell lung cancer, pancreatic
cancer, ovarian cancer and mesothelioma.

Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New
Hampshire, Malvern, Pennsylvania and New York City. Additionally, the
company has offices in Germany, Switzerland, Japan and Israel. For
additional information about the company, please visit
or follow us at

Forward-Looking Statements

In addition to historical facts or statements of current condition, this
press release may contain forward-looking statements. Forward-looking
statements provide Novocure's current expectations or forecasts of
future events. These may include statements regarding anticipated
scientific progress on its research programs, clinical trial progress,
development of potential products, interpretation of clinical results,
prospects for regulatory approval, manufacturing development and
capabilities, market prospects for its products, coverage, collections
from third-party payers and other statements regarding matters that are
not historical facts. You may identify some of these forward-looking
statements by the use of words in the statements such as "anticipate,"
"estimate," "expect," "project," "intend," "plan," "believe" or other
words and terms of similar meaning. Novocure's performance and financial
results could differ materially from those reflected in these
forward-looking statements due to general financial, economic,
regulatory and political conditions as well as more specific risks and
uncertainties facing Novocure such as those set forth in its Annual
Report on Form 10-K filed on February 22, 2018, with the U.S. Securities
and Exchange Commission. Given these risks and uncertainties, any or all
of these forward-looking statements may prove to be incorrect.
Therefore, you should not rely on any such factors or forward-looking
statements. Furthermore, Novocure does not intend to update publicly any
forward-looking statement, except as required by law. Any
forward-looking statements herein speak only as of the date hereof. The
Private Securities Litigation Reform Act of 1995 permits this discussion.


View Comments and Join the Discussion!